Epitopea Limited – Trademark Portfolio
Entity Type: 16
Epitopea Limited holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 2 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include EPITOPEA and CRYPTIGEN. The owner is based in Cambridge.
Salisbury House, Station Road
Cambridge 13354764 , GB
Showing of trademarks Trademarks
Trademark Classifications
Epitopea Limited's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Epitopea Limited have?
Epitopea Limited has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Epitopea Limited file in?
Epitopea Limited files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are Epitopea Limited's most well-known trademarks?
Epitopea Limited's registered trademark portfolio includes well-known marks such as EPITOPEA and CRYPTIGEN. These are among 2 currently registered trademarks in the portfolio.
What is Epitopea Limited's trademark registration success rate?
Epitopea Limited has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.